FORBION
PRIVATE EQUITY FIRM
Forbion is a dedicated life sciences VC firm with offices in the Netherlands and Germany that works with entrepreneurs to build life sciences companies with technologies designed to transform patient’s lives. Forbion invests in life sciences companies that are active in the (bio-)pharma space. Forbion’s investment team has built an impressive performance track record since the late nineties with successful investments in over 50 companies. Forbion manages well over €1 billion across ten funds. Besides financial objectives, Forbion selects investments that will positively affect health and well-being of patients. Forbion also operates a joint venture with BGV, which manages three separate seed and early stage funds focused on Benelux. Facts & Figures Bedrijf Forbion Hoofdkantoor Gooimeer 2-35, 1411 DC Naarden Website www.forbion.com Telefoonnummer +31 (0)35 699 3000 Actief in Nederland, Duitsland & Singapore Managing Partner(s) 3 Medewerkers 26 Actieve fondsen Forbion Fund IV Enterprise value portfoliobedrijven €10-500 miljoen Aantal bedrijven in portfolio 19 Aantal acquisities 2019 & 2020 Exits 2019 & 2020 5 Investeringsfocus Life Sciences Investeringstermijn 10 jaar Sectorfocus Biotech; Life sciences Average equity ticket €10-35 miljoen Investments Promedior, KaNDy, Infazome, Dyne (NASDAQ:DYN), Enterprise (op volgorde van laatst aangekochte)
Martien van Osch Managing Partner martien.van.osch@forbion.com
Martien van Osch is managing partner and splits his time between operational activities of the Firm and spearheading the medical device related activities at Forbion. He currently actively contributes to the boards of Mitralign and Autonomic Technologies.
Sander Slootweg Managing Partner +31 (0)35 699 3015 sander.slootweg@forbion.com
258 | MENA.NL/DEALMAKERS
Sander Slootweg is managing partner and co-founded ABN AMRO Capital Life Sciences in 2000 and Forbion in 2006. At Forbion, he is responsible for Fundraising, Investor- and Public Relations. On the portfolio management side, he currently serves on the boards of Forbion’s portfolio companies NorthSea Therapeutics, Replimune, Inc., Xention Discovery and Oxyrane Ltd.
